{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}],"title":"Anaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Iron deficiency anaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Leukocytosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Leukopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Thrombocytosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Hypokalaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Hypomagnesaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Hypocalcaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hyperglycaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypercreatininaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hyperuricaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypercalcaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypernatraemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypoalbuminaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyponatraemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Activated partial thromboplastin time prolonged"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Blood creatinine increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"C-reactive protein increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"International normalised ratio increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Alanine aminotransferase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Aspartate aminotransferase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blood alkaline phosphatase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blood bicarbonate decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Blood creatine phosphokinase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blood potassium decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Creatinine renal clearance decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Prothrombin time prolonged"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"White blood cell count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyperthyroidism"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypothyroidism"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hypertransaminasaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyperbilirubinaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Haematuria"}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"description":"Laboratory abnormalities that induced clinical signs or symptoms, required concomitant therapy or required changes during treatment emergent period were reported as TEAEs. Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.","groups":[{"description":"Participants received IV tisotumab vedotin 2.0 mg/kg Q3W until radiographic disease progression verified by the IRC, unacceptable AEs requiring drug discontinuation, withdrawal of consent, lost to follow up or death, whichever occurred first.","id":"OG000","title":"Tisotumab Vedotin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"FAS included all participants who received at least 1 dose of tisotumab vedotin.","reportingStatus":"POSTED","timeFrame":"From Day 1 through 30 days after the last dose of study drug (approximately 49 months)","title":"Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs","type":"SECONDARY","unitOfMeasure":"Participants"}